{"id":"placebo-to-ertugliflozin","safety":{"commonSideEffects":[{"rate":"0.1-0.5%","effect":"Ketoacidosis"},{"rate":"10-20%","effect":"Increased urination"},{"rate":"5-10%","effect":"Dehydration"},{"rate":"5-10%","effect":"Nausea"},{"rate":"2-5%","effect":"Vomiting"},{"rate":"2-5%","effect":"Hypotension"},{"rate":"0.1-0.5%","effect":"Increased risk of amputations"},{"rate":"2-5%","effect":"Increased risk of fractures"},{"rate":"2-5%","effect":"Increased risk of urinary tract infections"},{"rate":"2-5%","effect":"Increased risk of genital mycotic infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action leads to a decrease in glucose levels in the blood, which can help manage type 2 diabetes. By reducing glucose reabsorption, the kidneys excrete more glucose in the urine, further lowering blood glucose levels.","oneSentence":"Ertugliflozin works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:44.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"},{"name":"Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT04029480","phase":"PHASE3","title":"Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT04438213","phase":"PHASE2","title":"Ertugliflozin in Chronic Heart Failure","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-03-10","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT04600921","phase":"PHASE3","title":"Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2021-06-24","conditions":"Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators","enrollment":55},{"nctId":"NCT04231331","phase":"PHASE3","title":"Ertugliflozin for Functional Mitral Regurgitation","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2020-11-04","conditions":"Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction","enrollment":128},{"nctId":"NCT03717194","phase":"PHASE3","title":"Effect of Ertugliflozin on Cardiac Function in Diabetes","status":"COMPLETED","sponsor":"Soo Lim","startDate":"2019-06-01","conditions":"Type2 Diabetes, Heart Failure","enrollment":102},{"nctId":"NCT06580717","phase":"PHASE4","title":"ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-10-15","conditions":"Nonobstructive Hypertrophic Cardiomyopathy","enrollment":200},{"nctId":"NCT05152940","phase":"PHASE4","title":"ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-03-20","conditions":"Heart Failure With Reduced Ejection Fraction, Congestion","enrollment":28},{"nctId":"NCT04027530","phase":"PHASE4","title":"Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-12-10","conditions":"Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy","enrollment":40},{"nctId":"NCT01986881","phase":"PHASE3","title":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-04","conditions":"Type 2 Diabetes Mellitus","enrollment":8246},{"nctId":"NCT00989079","phase":"PHASE1","title":"A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-16","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01018823","phase":"PHASE1","title":"A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-14","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01054300","phase":"PHASE1","title":"Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-17","conditions":"Diabetes Mellitus, Type 2, Adult","enrollment":52},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT01096667","phase":"PHASE2","title":"Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-17","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":194},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01986855","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":468},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT01223339","phase":"PHASE1","title":"Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10","conditions":"Diabetes Mellitus, Type 2","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Ertugliflozin","genericName":"Placebo to Ertugliflozin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ertugliflozin works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}